General Information |
|
Product |
MAP3K8 Positive Control |
Description |
Western Blot Positive Control Mitogen-activated protein kinase kinase kinase 8 |
Verified Applications |
WB |
Immunogen |
Purified Protein |
Accession # |
GenBank: AAI13567.1 |
|
|
Quantity |
5 Applications |
Volume |
Inquire |
Form |
Western Blot Positive Control |
Storage |
-20⁰C for long term storage |
|
|
Western Blot |
1:500 |
|
|
Uniprot # |
|
Overview |
Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. |
Molecular Function |
Kinase, Serine/threonine-protein kinase, Transferase |
Subcellular Location |
Cytoplasm |
Expression |
Expressed in several normal tissues and human tumor-derived cell lines. |
Structure |
Forms a ternary complex with NFKB1/p105 and TNIP2. Interacts with NFKB1; the interaction increases the stability of MAP3K8 but inhibits its MEK phosphorylation activity, whereas loss of interaction following LPS stimulation leads to its degradation. Interacts with CD40 and TRAF6; the interaction is required for ERK activation. Interacts with KRS2; the interaction inhibits ERK and NF-kappa-B activation. |
Alternative Nomenclature |
c COT antibody Cancer Osaka thyroid oncogene antibody COT antibody COT proto oncogene serine/threonine protein kinase antibody EST antibody ESTF antibody Ewing sarcoma transformant antibody FLJ10486 antibody MEKK8 antibody Mitogen activated protein kinase kinase kinase 8 antibody Proto oncogene cCot antibody Serine/threonine-protein kinase cot antibody TPL 2 antibody Tumor progression locus 2 antibody |
Protein information supplied by UniProt
Product | Note | Status | Price | |
---|---|---|---|---|
|
MAP3K8-101AP | |||
|
MAP3K8-FITC | |||
|
P-MAP3K8 | |||
|
MAP3K8-BIOTIN | |||
Display accessory details |
Select your currency:
(c) FabGennix International Inc.